Vertex Pharmaceuticals, Inc. (VRTX) Blows Up Q3 Estimates
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $516.44 -1.77%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Vertex (VRTX): 'SION Overhang Cleared; We Would Remain Buyers'
- Innovaro (INV) Misses Q2 EPS by 9c
- KinderCare Learning Companies, Inc. (KLC) Misses Q2 EPS by 2c; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
